Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Behavioral Health topic
No spam. Unsubscribe anytime.
Committee advances medical‑psilocybin bill as amended; sponsors add veteran seat to advisory board, remove appropriation
Summary
Senate Bill 219, creating a regulated medical psilocybin program for a narrow set of qualifying conditions, drew extensive testimony from veterans, clinicians and first responders; the committee adopted amendments adding a veteran to the advisory board and stripping a direct appropriation before advancing a committee substitute.
The Senate Judiciary Committee heard extended testimony on Senate Bill 219, which would create a regulated medical‑psilocybin program limited initially to four qualifying conditions (post‑traumatic stress disorder, treatment‑resistant major depressive disorder, substance‑use disorder, and end‑of‑life anxiety). The bill delegates rulemaking and licensing authority to the Department of Health and establishes an advisory board, research and equity funds, and a medical‑only administration model (no at‑home use).
More than a dozen witnesses — including veterans, clinicians, hospice providers, and a firefighter union leader — described personal and clinical experience with psilocybin‑assisted therapy. A veteran testified, “It wasn't until I worked with psilocybin under guided care that I found healing.” Doctors and hospice clinicians cited peer‑reviewed research and clinical protocols supporting psilocybin‑assisted therapy for the targeted conditions.
Committee members asked technical questions about dosing, supply and whether synthetic formulations would be permitted. Sponsors said the bill focuses on whole‑product psilocybin (the natural compound), and the Department of Health would set clinical protocols and licensing requirements during the rulemaking process; the bill delays implementation so programs would not begin to operate until December 31, 2027, to allow the department and advisory board to develop standards. The chair and sponsors said the bill delegates protocol and safety design to the Department of Health and institutional partners such as university researchers.
The committee adopted an amendment that removed the appropriation language (the sponsors said House Bill 2 includes $2 million to stand up the program contingent on passage) and added a veteran member to the advisory board. Senators worked through concerns about clinical protocols, the difference between natural and synthetic products, and civil and criminal liability for clinicians; the committee clarified that clinicians would not be arrested or prosecuted for authorized program activities but would remain liable for negligent care.
Following debate the sponsor moved and the committee recorded a do‑pass recommendation on the Judiciary committee substitute for SB 219 (as amended). The committee also noted the program's long implementation runway and the Department of Health’s role in developing clinical standards.
